OKG Capital
To add a bio or update investment portfolio, please click update information.
Investment Portfolio
OXcan
9 Jan 2025
OXcan raises £9m Series A led by We Venture Capital and Cross-Border Impact Ventures to revolutionise early lung cancer detection
OXcan develops blood-based liquid biopsy tests using proteomics and AI to detect lung cancer at earlier stages, enabling minimally invasive screening designed to improve outcomes and reduce pressure on healthcare systems.
52North
6 Dec 2024
Oncology medical tech startup 52North secures £5m with landmark UK-US hospital VC deal
52North builds medical devices and digital tools that support cancer patients outside hospital, focusing on early detection and monitoring of treatment-related complications to improve urgent oncology care pathways.
More venture news
- 21 Sept 2026
SpriveSprive unlocks an £8m Series A from VCs to help homeowners pay down their mortgages
Series AFintech - 17 Sept 2026
MagenticMagentic closes £13m Series A led by Felicis to put AI workers inside the procurement teams of global manufacturers
Series ASupply Chain - 15 Sept 2026
Jack & JillJack & Jill unlocks £30m Series A led by Air Street Capital to run dual-agents on both sides of hiring market
Series AHR
